Galactonojirimycin derivatives restore mutant human β-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse
- 31 August 2001
- journal article
- research article
- Published by Elsevier in Brain & Development
- Vol. 23 (5), 284-287
- https://doi.org/10.1016/s0387-7604(01)00216-9
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N -butyldeoxynojirimycinProceedings of the National Academy of Sciences, 1999
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999
- Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N -ButyldeoxynojirimycinScience, 1997
- Neurological manifestations of knockout mice with β-galactosidase deficiencyBrain & Development, 1997
- β-Galactosidase-deficient mouse as an animal model for GM1-gangliosidosisGlycoconjugate Journal, 1997
- Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Identification of point mutations in Japanese patients with Lesch-Nyhan syndrome and hereditary gout and their permanent expression in an HPRT-deficient mouse cell lineHuman Genetics, 1994
- Intracellular processing and maturation of mutant gene products in hereditary ?-galactosidase deficiency (?-galactosidosis)Human Genetics, 1994
- Lysosomal glycosphingolipid storage in chloroquine-induced ?-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry diseaseActa Neuropathologica, 1993
- Galactosialidosis (β-galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of β-galactosidase moleculesClinica Chimica Acta; International Journal of Clinical Chemistry, 1982